The course of inflammatory bowel disease during pregnancy and postpartum: A prospective European ECCO-EpiCom Study of 209 pregnant women

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 5, 2013, Pages 501-512

  Pedersen, N ^a   Bortoli, A ^b   Duricova, D ^c   Dinca, R ^d   Panelli, M R ^e   Gisbert, J P ^f   Zoli, G ^g   Lopez Sanroman A ^h   Castiglione, F ⁱ   Riegler, G ^j   Annese, V ^k   Gionchetti, P ^l   Prada, A ^b   Pont, E D ^d   Timmer, A ^m   Felley, C ⁿ   Shuhaibar, M ^o   Tsianos, E V ^p   Dejaco, C ^q   Baert, F J ^r   Jess, T ^s   Lebech, M ^a   Hommes, D W ^t   Munkholm, P ^a   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b RHO HOSPITAL   (Italy)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g Cento Hospital   (Italy)

^h Roman y Cajal   (Spain)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^k San Giovanni ^*  (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

ⁿ UNIVERSITY OF LAUSANNE   (Switzerland)

^o ADELAIDE AND MEATH HOSPITAL   (Ireland)

^p UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^q UNIVERSITY OF VIENNA   (Austria)

^r Heilig Hartziekenhus   (Belgium)

^s STATENS SERUM INSTITUT   (Denmark)

^t University Hospital   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; EUROPE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; REMISSION; RISK FACTOR; SECOND TRIMESTER PREGNANCY; ULCERATIVE COLITIS;

EID: 84882453590     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12412     Document Type: Article

References (43)

1. Vind I, Riis L, Jess T, et al,. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-82.
2. Langholz E, Munkholm P, Nielsen OH, et al,. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
3. Munkholm P, Langholz E, Nielsen OH, et al,. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 609-14.
4. Shivananda S, Lennard-Jones J, Logan R, et al,. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-7.
5. Cornish J, Tan E, Teare J, et al,. A meta-Analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-7.
6. Bortoli A, Pedersen N, Duricova D, et al,. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011; 34: 724-34.
7. Dominitz JA, Young JC, Boyko EJ,. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol 2002; 97: 641-8.
8. Fonager K, Sorensen HT, Olsen J, et al,. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426-30.
9. Mahadevan U, Sandborn WJ, Li DK, et al,. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-12.
10. Norgard B, Hundborg HH, Jacobsen BA, et al,. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102: 1947-54.
11. Stephansson O, Larsson H, Pedersen L, et al,. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011; 17: 795-801.
12. Agret F, Cosnes J, Hassani Z, et al,. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 509-13.
13. Castiglione F, Pignata S, Morace F, et al,. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol 1996; 28: 199-204.
14. Mogadam M, Korelitz BI, Ahmed SW, et al,. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75: 265-9.
15. Nielsen OH, Andreasson B, Bondesen S, et al,. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-42.
16. Nielsen OH, Andreasson B, Bondesen S, et al,. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984; 19: 724-32.
17. Khosla R, Willoughby CP, Jewell DP,. Crohn's disease and pregnancy. Gut 1984; 25: 52-6.
18. Miller JP,. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986; 79: 221-5.
19. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
20. Walmsley RS, Ayres RC, Pounder RE, et al,. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
21. Best WR,. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006; 12: 304-10.
22. Higgins PD, Schwartz M, Mapili J, et al,. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8.
23. Shein-Chung Chow HWJS,. Sample Size Calculations in Clinical Research. 2008.
24. Van AG, Dignass A, Reinisch W, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
25. Dignass A, Van AG, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
26. van der Woude CJ, Kolacek S, Dotan I, et al,. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493-510.
27. de Lima A, Zelinkova Z, van der Ent C, et al,. Disease relapse rates during pregnancy-results from the Erasmus MC Roterdam prospective cohort. J Crohns Colitis 2013; 7 (Suppl. 1): 653: S274.
28. Julsgaard M, Norgaard M, Hvas CL, et al,. Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis. Inflamm Bowel Dis 2011; 17: 1573-80.
29. Nielsen MJ, Norgaard M, Holland-Fisher P, et al,. Self-reported antenatal adherence to medical treatment among pregnant women with Crohn's disease. Aliment Pharmacol Ther 2010; 32: 49-58.
30. Rahimi R, Nikfar S, Rezaie A, et al,. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-Aminosalicylic acid drugs: a meta-Analysis. Reprod Toxicol 2008; 25: 271-5.
31. Francella A, Dyan A, Bodian C, et al,. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
32. Goldstein LH, Dolinsky G, Greenberg R, et al,. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701.
33. Peyrin-Biroulet L, Oussalah A, Roblin X, et al,. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther 2011; 33: 707-13.
34. Coelho J, Beaugerie L, Colombel JF, et al,. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
35. Angelucci E, Cocco A, Viscido A, et al,. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm Bowel Dis 2008; 14: 435-6.
36. Katz JA, Antoni C, Keenan GF, et al,. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
37. Mahadevan U, Kane S, Sandborn WJ, et al,. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-8.
38. Srinivasan R,. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001; 96: 2274-5.
39. Zelinkova Z, de Haar C, de Ridder L, et al,. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-8.
40. Gisbert JP,. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010; 16: 881-95.
41. Iaccarino L, Ghirardello A, Zen M, et al,. Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus. Reumatismo 2012; 64: 314-20.
42. Sykes L, Macintyre DA, Yap XJ, et al,. Changes in the Th1:Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2. Mediators Inflamm 2012; 2012: 416739.
43. Riis L, Vind I, Politi P, et al,. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101: 1539-45.